Literature DB >> 26998220

Intermediate hepatocellular carcinoma: the role of transarterial therapy.

Fabrizio Chegai1, Antonio Orlacchio2, Stefano Merolla2, Serena Monti3, Lorenzo Mannelli4.   

Abstract

According to Barcelona Clinic Liver Cancer, the recommended first-line treatment for patients with intermediate stage of hepatocellular carcinoma (HCC) is transarterial chemoembolization. Patients with intermediate stage of HCC represent 20% with a 2-year survival of approximately 50%. Nowadays, transarterial therapies have proved precious in the treatment of hepatic malignancies. During the last years, there were important developments in practiced transarterial therapies and their efficacy is still controversial. The purpose of this review is to discuss in further details these transarterial therapies that have been used to treat cases of HCC.

Entities:  

Keywords:  DEB TACE; chemoembolization; embolization; hepatocellular carcinoma; interventional treatment; radioembolization; transarterial chemo-occlusion; transarterial therapy

Year:  2015        PMID： 26998220      PMCID： PMC4792112          DOI： 10.2217/hep.15.32

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


  88 in total

Review 1.  Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.

Authors:  Riccardo Lencioni
Journal:  Crit Rev Oncol Hematol       Date:  2011-12-03       Impact factor: 6.312

Review 2.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

3.  Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization.

Authors:  Shiro Miyayama; Osamu Matsui; Keiichi Taki; Tetsuya Minami; Yasuji Ryu; Chiharu Ito; Koichi Nakamura; Dai Inoue; Kazuo Notsumata; Daisyu Toya; Nobuyoshi Tanaka; Takeshi Mitsui
Journal:  Cardiovasc Intervent Radiol       Date:  2006 Jan-Feb       Impact factor: 2.740

4.  A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.

Authors:  Wei-Ping Zhou; Eric C H Lai; Ai-Jun Li; Si-Yuan Fu; Jian-Ping Zhou; Ze-Ya Pan; Wan Yee Lau; Meng-Chao Wu
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

5.  Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria.

Authors:  Daniel B Brown; Jennifer E Gould; Debra A Gervais; S Nahum Goldberg; Ravi Murthy; Steven F Millward; William S Rilling; Jean-Francois S Geschwind; Riad Salem; Suresh Vedantham; John F Cardella; Michael C Soulen
Journal:  J Vasc Interv Radiol       Date:  2009-07       Impact factor: 3.464

6.  Prognostic significance of the lymphocyte-to-neutrophil ratio in percutaneous fine-needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma.

Authors:  Yasuharu Nakahara; Yoshiro Mochiduki; Yoshihiro Miyamoto; Yukiko Nakahara; Yoshitaka Katsura
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

7.  In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

Authors:  Amr El Fouly; Judith Ertle; Ahmed El Dorry; Mohamed K Shaker; Alexander Dechêne; Heba Abdella; Stefan Mueller; Eman Barakat; Thomas Lauenstein; Andreas Bockisch; Guido Gerken; Joerg F Schlaak
Journal:  Liver Int       Date:  2014-08-02       Impact factor: 5.828

Review 8.  Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.

Authors:  Roberto S Oliveri; Jørn Wetterslev; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

9.  Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up.

Authors:  Guido Bonomo; Vittorio Pedicini; Lorenzo Monfardini; Paolo Della Vigna; Dario Poretti; Gianluigi Orgera; Franco Orsi
Journal:  Cardiovasc Intervent Radiol       Date:  2009-12-03       Impact factor: 2.740

10.  Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study.

Authors:  Hideyuki Nishiofuku; Toshihiro Tanaka; Masaki Matsuoka; Toshio Otsuji; Hiroshi Anai; Satoru Sueyoshi; Yoshitaka Inaba; Fumikazu Koyama; Masayuki Sho; Yoshiyuki Nakajima; Kimihiko Kichikawa
Journal:  J Vasc Interv Radiol       Date:  2012-11-26       Impact factor: 3.464
View more
  7 in total

1.  Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety.

Authors:  Jia-Yan Ni; Hong-Liang Sun; Yao-Ting Chen; Jiang-Hong Luo; Wei-Dong Wang; Xiong-Ying Jiang; Dong Chen; Lin-Feng Xu
Journal:  J Cancer Res Clin Oncol       Date:  2017-10-09       Impact factor: 4.553

2.  Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Silvia Roma; Stefano Merolla; Alessandra Bosa; Simona Francioso
Journal:  Radiol Med       Date:  2019-10-03       Impact factor: 3.469

3.  68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies.

Authors:  Elise Verger; Pierre Drion; Geneviève Meffre; Claire Bernard; Luc Duwez; Nicolas Lepareur; Olivier Couturier; François Hindré; Roland Hustinx; Franck Lacoeuille
Journal:  PLoS One       Date:  2016-10-14       Impact factor: 3.240

4.  Upregulation of P2Y2 nucleotide receptor in human hepatocellular carcinoma cells.

Authors:  Eunyoung Tak; Dae Young Jun; Seok-Hwan Kim; Gil-Chun Park; Jooyoung Lee; Shin Hwang; Gi-Won Song; Sung-Gyu Lee
Journal:  J Int Med Res       Date:  2016-11-02       Impact factor: 1.671

5.  Repeated Transarterial Chemoembolization with Degradable Starch 
Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Simona Francioso; Stefano Merolla; Serena Monti; Mario Angelico; Giuseppe Tisone; Lorenzo Mannelli
Journal:  Curr Med Imaging Rev       Date:  2018-08

6.  Hyaluronic acid-based nano-sized drug carrier-containing Gellan gum microspheres as potential multifunctional embolic agent.

Authors:  Ming Fang Hsu; Yen Sheng Tyan; Yu Chen Chien; Ming Wei Lee
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

Review 7.  Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update.

Authors:  Sirish A Kishore; Raazi Bajwa; David C Madoff
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.